The pivotal 2021 clinical trial of semaglutide revealed that nearly 14% of participants were unable to lose even 5% of their body weight, despite being on the medication for over a year
Pers Med
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Heres how getting started with Hims works: Online assessment
Address your health issues and recovery process the quick way, experience faster improvements in your overall health today